Clinical Trial Update: A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluated EB-1010 at 50 mg/day and 100 mg/day against paroxetine and placebo in outpatients with major depressive disorder inadequat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• EB-1010 (EB-1010)
• Paroxetine (Paroxetine hydrochloride)

Snippet

Sponsor: Euthymics BioScience, Inc. | Conditions: Major Depressive Disorder | Phase 2, Phase 3 | Status: COMPLETED